Industry Report Tracks Innovation’s Value To AIDS Treatment In Developing Countries 18/07/2016 by William New, Intellectual Property Watch 2 Comments A new report launched in time for this week’s AIDS conference in South Africa analyzes factors relating to access to HIV/AIDS treatments over the past 15 years. The analysis includes a look at government policies used during that time, the contribution of generic and research-based industries, and the importance of voluntary licensing.
Orphan Drugs Finding Home In Markets: Could Be 20% Of All Sales By 2020 15/07/2016 by Intellectual Property Watch 2 Comments Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market “could only dream about” with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage.
Opposition To Kenyan “Anti-Innovation” ICT Bill Grows 13/07/2016 by Maina Waruru for Intellectual Property Watch 1 Comment A bill introduced in Kenya’s parliament intended to streamline, govern and regulate the country’s information and communications technology (ICT) sector has been met with opposition from different quarters over fears that it could put ICT technicians out of practice and stifle the country’s innovation capacity if passed into law.
Post-Huawei v ZTE: Are FRAND Negotiations Finally More Balanced In Europe? 13/07/2016 by Magda Voltolini for Intellectual Property Watch 1 Comment BARCELONA, Spain — The Huawei v ZTE Case C – 170/13, 21 July 2015 prescribed some guidelines for fair, reasonable and non-discriminatory (FRAND) licensing negotiations, for both standard-essential patent holders and users. A recent private-sector panel addressed European FRAND case law and the latest information and communications technology industry policy opinions, in particular concerning royalty assessment rate (end-user or technology), royalty stacking, patent pool approach and injunctions.
How Are Licensors And Licensees Adapting To New Scenarios? 12/07/2016 by Magda Voltolini for Intellectual Property Watch Leave a Comment BARCELONA, Spain — A recent industry conference panel here covered topics of changing intellectual property scenarios perceived from different angles, in particular from operating companies which manufacture products or services and patent assertion entities (PAEs).
Focus On Medicines Patents & Prices Alone May Do More Harm Than Good 12/07/2016 by Intellectual Property Watch Leave a Comment Populism is in vogue these days and critics of pharmaceutical patents are trying to ride the wave, claiming that undermining patents will dramatically decrease prices but not reduce innovation. Both sides of that claim are flawed, writes Steven Tepp.
V4 Countries Launch Visegrad Patent Institute As Region’s First ISA, IPEA 08/07/2016 by Jaroslaw Adamowski for Intellectual Property Watch Leave a Comment With the aim of strengthening regional cooperation in intellectual property, the four member states of the Visegrad Group, which comprises Poland, Hungary, the Czech Republic and Slovakia, launched the Visegrad Patent Institute (VPI) on 1 July. Applicants will be allowed to communicate with the institutions in their respective mother tongues, and fees for Patent Cooperation Treaty (PCT) applications will be reduced by as much as 40 percent, according to Poland’s Patent Office (UPRP).
PIP Framework Review Ongoing; Last Call For Country Submissions 06/07/2016 by Catherine Saez, Intellectual Property Watch 1 Comment World Health Organization member states have until 15 July to submit views on a five-year-old mechanism allowing for swifter sharing of pandemic influenza viruses and benefit-sharing measures, according to the group tasked with providing a report on the review.
US Industry Airs Hopes, Frustrations On IP Rights In India 05/07/2016 by Patralekha Chatterjee for Intellectual Property Watch Leave a Comment What do global innovators make of India’s new National Intellectual Property Rights Policy? A recent discussion on “India’s National IPR Strategy: A View from Global Innovators” in Washington DC attempted to assess the opportunities and challenges ahead from the perspective of American companies.
The Dutch & Pharma Policy: A Groundbreaking Presidency 05/07/2016 by Intellectual Property Watch 1 Comment The Netherlands’ Presidency of the European Council proved to be far from quiet in relation to pharmaceutical affairs. June 17 was the concluding Health Ministers Council (EPSCO) that signed off the most strongly-worded conclusions Brussels observers can recall. The meeting signaled the end of an overall successful and impactful Presidency in the highly sensitive field of medicines. The past semester has been eventful to say the least.